Anumana Receives U.S. FDA Breakthrough Device Designation for its Cardiac Amyloidosis Algorithm
Related Articles
BOSTINNO’S 2021 INNO ON FIRE: Meet the 50 startups and individuals setting Boston’s innovation ecosystem ablaze.
Biz Journals: If 2020 was a strange year for Boston's startups, companies and nonprofits, 2021 was its equally weird sequel. But the continuing pandemic, global supply-chain shortages, economic turmoil and…November 10, 2021
Pfizer to partner with Mayo Clinic spinoff on early cardiac amyloidosis detection
Medtech Dive: Anumana, a health technology startup spun out of Mayo Clinic, entered a multi-year agreement with Pfizer to develop an algorithm to detect cardiac amyloidosis, a serious heart condition.…December 16, 2022
Anumana Named to Fierce Medtech’s 2022 Fierce 15
AI-driven startup from nference and Mayo Clinic Platform positioned to transform cardiac careMarch 20, 2023
J&J Hired Thousands of Data Scientists. Will The Strategy Pay Off?
WSJ: One project—with the Mayo Clinic and a health-technology company called Anumana based in Cambridge, Mass.—aims to speed up diagnosis of high blood pressure in the lungs, or pulmonary hypertension.…November 30, 2023